Oragenics' CMO will participate in the Brain Health Summit, discussing concussion prevention and treatment advancements.
Quiver AI Summary
Oragenics, Inc. has announced that its Chief Medical Officer, Dr. James P. Kelly, will participate as a panelist at the 12th Annual Brain Health Summit on February 8, 2025, coinciding with the Super Bowl in New Orleans. The summit aims to enhance awareness and care for athletic concussions and tackle innovative treatment approaches for traumatic brain injuries (TBI). Dr. Kelly, an expert in neurology and concussion care, will discuss the long-term effects of TBIs and advancements in treatment, highlighting Oragenics' research on ONP-002, an intranasal neurosteroid for concussion treatment. The event, hosted by Leigh Steinberg, will bring together leading figures in sports and medicine to promote player safety and brain health.
Potential Positives
- Dr. James P. Kelly's participation as a featured panelist at the prestigious 12th Annual Brain Health Summit enhances Oragenics' visibility and credibility in the field of concussion treatment and brain health.
- The summit's focus on advancing awareness and innovative approaches to traumatic brain injury aligns with Oragenics' mission and highlights their commitment to addressing critical health issues in athletics.
- The announcement showcases Oragenics' leading role in innovation with its neurosteroid product, ONP-002, drawing attention to their unique solutions for unmet needs in concussion treatment.
Potential Negatives
- Dr. Kelly's participation in the event may suggest that the company is struggling to gain traction in the competitive field of concussion treatment.
- The press release includes a caution about forward-looking statements, which may indicate uncertainties surrounding the company’s future developments and financial performance.
FAQ
What is the Brain Health Summit?
The Brain Health Summit is an annual event focused on advancing awareness, prevention, and treatment of athletic concussions and brain injuries.
Who is Dr. James P. Kelly?
Dr. James P. Kelly is the Chief Medical Officer of Oragenics and a leading expert in neurology and concussion care.
What is ONP-002?
ONP-002 is Oragenics' intranasal neurosteroid designed to address the unmet needs of concussion treatment.
When and where is the summit taking place?
The summit will be held on February 8, 2025, in New Orleans, coinciding with the Super Bowl celebrations.
Who moderates the Brain Health Summit?
This year's summit will be moderated by Dr. Nicole Roberts, an expert in health innovation and brain health.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$OGEN Insider Trading Activity
$OGEN insiders have traded $OGEN stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $OGEN stock by insiders over the last 6 months:
- FRED TELLING sold 3,597 shares for an estimated $1,294
- ALAN W DUNTON sold 66 shares for an estimated $23
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$OGEN Hedge Fund Activity
We have seen 8 institutional investors add shares of $OGEN stock to their portfolio, and 5 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- HRT FINANCIAL LP added 27,918 shares (+inf%) to their portfolio in Q3 2024, for an estimated $10,642
- RENAISSANCE TECHNOLOGIES LLC removed 22,528 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $8,587
- CITADEL ADVISORS LLC removed 16,510 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $6,293
- VIRTU FINANCIAL LLC added 8,697 shares (+71.4%) to their portfolio in Q3 2024, for an estimated $3,315
- GEODE CAPITAL MANAGEMENT, LLC added 4,233 shares (+13.4%) to their portfolio in Q3 2024, for an estimated $1,613
- TOWER RESEARCH CAPITAL LLC (TRC) added 2,541 shares (+50.3%) to their portfolio in Q3 2024, for an estimated $968
- MORGAN STANLEY added 1,000 shares (+100000.0%) to their portfolio in Q3 2024, for an estimated $381
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
SARASOTA, Fla., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, today announced that its Chief Medical Officer, James P. Kelly, MA, MD, FAAN, FANA, will be a featured panelist at the 12th Annual Brain Health Summit, held in conjunction with this year’s Super Bowl celebrations in New Orleans on February 8, 2025. The event will focus on advancing awareness, prevention, and care for athletic concussions and exploring innovative approaches to traumatic brain injury (TBI) treatment.
Dr. Kelly, a leading expert in neurology and concussion care, joins an esteemed lineup of thought leaders to discuss the long-term impact of TBIs, groundbreaking advances in treatment, and strategies for prevention. His expertise aligns with the summit's mission to educate and inspire action in tackling the ongoing challenges posed by brain injuries in athletics.
“It’s an honor to contribute to this milestone event, which brings critical attention to the prevention and treatment of traumatic brain injuries,” said Dr. Kelly. “At Oragenics, we are at the forefront of innovation with ONP-002, our intranasal neurosteroid, designed to address the unmet needs of concussion treatment. Events like this summit are vital for fostering collaboration and exploring new approaches, such as leveraging neuroplasticity and advanced delivery systems, to transform how we care for athletes and others affected by TBIs.”
Now in its 12th year, the Brain Health Summit has become a cornerstone event for advancing the understanding and treatment of brain injuries in athletes. Hosted by legendary sports agent Leigh Steinberg, a long-time advocate for player safety and concussion awareness, the summit brings together top medical experts, former professional athletes, and industry leaders to drive meaningful change in brain health. This year’s event will once again feature Dr. Nicole Roberts as the moderator, who is the founder and President of Health & Human Rights Strategies and an expert in health innovation, technology, and brain health, particularly as it impacts vulnerable populations. Held alongside the excitement of the Super Bowl, the summit combines the sports community's passion with a commitment to improving the lives of those affected by TBIs.
Investor Contact
Rich Cockrell
404.736.3838
[email protected]
About Oragenics, Inc.
Oragenics is a development-stage biotechnology company focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI), also known as concussion, and for treating Niemann Pick Disease Type C (NPC), as well as proprietary powder formulation and an intranasal delivery device. For more information, please visit
www.oragenics.com
.
Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to, those described in our Form 10-K and other filings with the U.S. Securities and Exchange Commission. All information set forth in this press release is as of the date hereof. You should consider these factors in evaluating the forward-looking statements included in this press release and not place undue reliance on such statements. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, circumstances should change, except as otherwise required by law.